Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First report of dual KRAS Y96C/Y96S resistance mutations detected by liquid biopsy in KRAS G12C-mutant metastatic colorectal cancer.

The oncologist - 8 Jul 2026

Wang ZhiYu, Hong Dan, Zhang Lan, Qin Yan, Guo ZhiGui, Huo Yue, Shi Yan, Lu Yi, Li Bing, Su ShenYong

Abstract excerpt

BACKGROUND: Acquired resistance limits the long-term efficacy of KRAS G12C inhibitors in metastatic colorectal cancer (mCRC). While feedback signaling is a known resistance driver, the clinical evolution of structural alterations within the drug-binding pocket remains poorly characterized. CASE PRESENTATION: We present a patient with microsatellite-stable (MSS) KRAS G12C-mutated mCRC who progressed after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Liquid Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 42474245
DOI: 10.1093/oncolo/oyag263
PMCID: PMC13401486

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First report of dual KRAS Y96C/Y96S resistance mutations detected by liquid biopsy in KRAS G12C-mutant metastatic colorectal cancer.PMID 42474245Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.Semantic proximity Read ↗

Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.Semantic proximity Read ↗

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal CancerSemantic proximity Read ↗

Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden.Semantic proximity Read ↗

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.Semantic proximity Read ↗

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.Semantic proximity Read ↗

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.